Idarubicine
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Technische Universität DresdenPhase 4 / ApprovedDormant
A
81/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 71/ 100
- Competitive Position
- 95/ 100
Competitive context
20 Active assets in the Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vesanoid The Affiliated People's Hospital of Ningbo University | Phase 4 | A |
Cytosin-Arabinosid Associazione Italiana Ematologia Oncologia Pediatrica | Phase 4 | A |
Arsenic Trioxide Quetzal Therapeutics | Phase 4 | BBB |
Mitoxantrone Technische Universität Dresden | Phase 4 | BBB |
METHOTREXATE Technische Universität Dresden | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Idarubicine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →